Influence of Aspirin Usage on Blood Pressure: Dose and Administration-Time Dependencies

References

• Cornélissen G, Halberg F, Prikryl P, Dankova E, Siegelova J, Dusek J, International Womb-to-Tomb Chronome Study Group. Prophylactic aspirin treatment: the merits of timing. J Am Med Assn 1991; 266: 3128–29
   PubMed Web of Science ®Google Scholar
• Johansson B B, Norrving B, Widner H, Wu J, Halberg F. Stroke incidence: circadian and circaseptan (about weekly) variations in onset. Chronobiology: its role in clinical medicine, general biology, and agriculture, part A, D K Hayes, J E Pauly, R J Reiter. Wiley-Liss, New York 1990; 427–36
   Google Scholar
• Haus E, Cusulos M, Sackett-Lundeen L, Swoyer J. Circadian variations in blood coagulation parameters, alpha-anatrypsin antigen and platelet aggregation and retention in clinically healthy subjects. Chronobiol Internal 1990; 7: 203–16
   PubMed Web of Science ®Google Scholar
• Gregoire C, Labrecque G. Chronopharmacology of increasing doses of collagen and aspirin on the in vitro platelet aggregation [abstract]. Biological Rhythms and Medications: Proc Sixth Int Conf Chronopharmacol Chronotherapeutics. Amelia Island, Florida July 5–9, 1994; xiv-1
   Google Scholar
• Markiewicz A, Semenowicz K. Time dependent changes in the pharmacokinetics of aspirin. Int J Clin Pharmacol Biopharm 1979; 17: 409–11
   PubMedGoogle Scholar
• Reinberg A, Zagula-Mally Z W, Ghata J, Halberg F. Circadian rhythm in duration of salicylate excretion referred to phase of excretory rhythm and routine. Proc Soc Exp Biol (NY) 1967; 124: 826–32
   PubMed Web of Science ®Google Scholar
• Reinberg A, Clench J, Ghata J, Albuker F, Dupont J, Zagula-Mally Z W. Rhythmes circadiens de l'excretion urinaire du salicylate (chronopharmacocinétique) chez l'adulte sain. C R Acad Sci (Paris) 1975; 280: 1697–1700
   Google Scholar
• Labrecque G, Reinberg A. Chronopharmacology of nonsteroid anti-inflammatory drugs. Chronopharmacology: cellular and biochemical interactions, B Lemmer. Marcel Dekker, New York 1989; 545–79
   Google Scholar
• Takahashi R, Halberg F, Walker C A. Toward chronopharmacology. Pergamon Press, Oxford 1982
   Google Scholar
• Lemmer B. Chronopharmacology: cellular and biochemical interactions. Marcel Dekker, New York 1989
   Google Scholar
• Reinberg A, Smolensky M, Labrecque G. Annual review of chronopharmacology. Pergamon Press, Oxford 1990; Vol 7
   Google Scholar
• Touitou Y, Haus E. Biologic rhythms in clinical and laboratory medicine. Springer-Verlag, Berlin 1992
   Google Scholar
• Moore J G, Goo R H. Day and night aspirin-induced gastric mucosal damage and protection by ranitidine in man. Chronobiol Internat 1987; 4: 111–16
   PubMed Web of Science ®Google Scholar
• Moore J G. Chronobiology of the gastrointestinal system. Biologic rhythms in clinical and laboratory medicine, Y Touitou, E Haus. Springer-Verlag, Berlin 1992; 410–17
   Google Scholar
• Manson J E, Stampfer M J, Colditz G A, Willet W C, Rosner B, Speizer F E, Hennek-Ens C H. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. J Am Med Assn 1991; 266: 521–27
   PubMed Web of Science ®Google Scholar
• Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313–20
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129–35
   PubMed Web of Science ®Google Scholar
• Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. J Am Med Assn 1980; 243: 661–69
   PubMed Web of Science ®Google Scholar
• Lewis H D, Davis J W, Archibald D G, Steinke W E, Smitherman T C, Doherty J E, Schnaper H W, LeWinter M M, Linares E, Pouget J M, Sabharwal S C, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration cooperative study. N Engl J Med 1983; 309: 396–403
   PubMed Web of Science ®Google Scholar
• The ESPS Group. The European stroke prevention study (ESPS) principal end-points. Lancet 1987; 1: 1351–57
   Google Scholar
• Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320–31
   PubMed Web of Science ®Google Scholar
• Hennekens C H, Peto R, Hutchison G B, Doll R. An overview of the British and American aspirin studies. N Engl J Med 1988; 318: 923–24
   PubMed Web of Science ®Google Scholar
• Hennekens C H, Buring J E, Sandercock R, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80: 749–56
   PubMed Web of Science ®Google Scholar
• Stein B, Fuster V, Halperin J L, Chesebro J H. Antithrombotic therapy in cardiac disease: an emerging approach based on pathogenesis and risk. Circulation 1989; 80: 1501–13
   PubMed Web of Science ®Google Scholar
• The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827–30
   PubMed Web of Science ®Google Scholar
• The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg v. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261–66
   PubMed Web of Science ®Google Scholar
• The SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345–49
   PubMed Web of Science ®Google Scholar
• Goldhaber S Z, Manson J E, Stampfer M J, LaMotte F, Rosner B, Buring J E, Hennekens C H. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 1992; 340: 143–45
   PubMed Web of Science ®Google Scholar
• Manson J E, Tosteson H, Ridker P M, Satterfield S, Hebert R, O'Connor G T, Buring J E, Hennekens C H. The primary prevention of myocardial infarction. N Engl J Med 1992; 326: 1406–16
   PubMed Web of Science ®Google Scholar
• IS1S-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3, a randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753–70
   PubMed Web of Science ®Google Scholar
• Willard J E, Lange R A, Hillis L D. The use of aspirin in ischemic heart disease. N Engl J Med 1992; 327: 175–81
   PubMed Web of Science ®Google Scholar
• Fuster V, Dyken M L, Vokonas P S, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993; 87: 659–75
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81–106
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994; 308: 159–68
   PubMedGoogle Scholar
• Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994; 308: 235–46
   PubMed Web of Science ®Google Scholar
• 1986 guidelines for study of mild hypertension. Bull. WHO 1986; 64: 31–35
   PubMed Web of Science ®Google Scholar
• Association for the Advancement of Medical Instrumentation. American National Standard for Electronic or Automated Sphygmomanometers. AAMI, Washington, DC 1987
   Google Scholar
• White W B, Lund-Johansen P, McCabe E J. Clinical evaluation of the Colin ABPM 630 at rest and during exercise: an ambulatory blood pressure monitor with gas-powered cuff inflation. J Hypertens 1989; 7: 477–83
   PubMed Web of Science ®Google Scholar
• Cornélissen G. Instrumentation and data analysis methods needed for blood pressure monitoring in chronobiology. Chro-nobiotechnology and chronobiological engineering, L E Scheving, F Halberg, C F Ehret. Martinus Niijhoff, DordrechtThe Netherlands 1987; 241–261, NATO ASI Series No. 120
   Google Scholar
• Staessen J, Fagard R, Lijnen P, Thijs L, Vaa Hoof R, Amery A. Ambulatory blood pressure monitoring in clinical trials. J Hypertens 1991; 9(Suppl. 1)s13–s19
   Google Scholar
• Mojón A, Fernández J R, Hermida R C. Chronolab: an interactive software package for chronobiologic time series analysis written for the Macintosh™ computer. Chronobiol Internal 1992; 9: 403–12
   PubMed Web of Science ®Google Scholar
• Bingham C, Arbogast B, Cornélissen G, Lee J K, Halberg F. Inferential statistical methods for estimating and comparing cosinor parameters. Chronobiologia 1982; 9: 397–39
   PubMedGoogle Scholar
• Hermida R C. Chronobiologic data analysis systems with emphasis in chronothera-peutic marker rhythmometry and chronoepidemiologic risk assessment. Chronobiotechnology and chronobiological engineering, L E Schev-Ing, F Halberg, C F Ehret. Martinus Niijhoff, DordrechtThe Netherlands 1987; 88–119, NATO ASI Series No. 120
   Google Scholar
• Nelson W, Tong Y L, Lee J K, Halberg F. Methods for cosinor rhythmometry. Chronobiologia 1979; 6: 305–23
   PubMedGoogle Scholar
• Hermida R C, Mojón A, Fernández J R, Ayala D E. Computer-based medical system for the computation of blood pressure excess in the diagnosis of hypertension. Biomed Instrum Technol 1996; 30: 267–83
   PubMedGoogle Scholar
• Lemmer B. Cardiovascular chronobiology and chronopharmacology. Biologic rhythms in clinical and laboratory medicine, Y Touitou, E Haus. Springer-Verlag, Berlin 1992; 418–27
   Google Scholar
• Halberg F, Cornélissen G. Consensus concerning the chronome and the addition to statistical significance of scientific signification. Biochimica Clinica 1991; 15: 159–62
   Google Scholar
• Hermida R C, Fernández J R, Ayala D E, Iglesias M, Halberg F. Time-dependent effects of ASA administration on blood pressure in healthy subjects. Chronobiologia 1994; 21: 201–13
   PubMedGoogle Scholar
• Clarke R J, Mayo G, Price P, FitzGerald G A. Suppression of thromboxane A2 but not systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325: 1137–41
   PubMed Web of Science ®Google Scholar
• Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromoboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366–72
   PubMed Web of Science ®Google Scholar
• Walsh S W, Wang Y, Kay H H, McCoy M C. Low-dose aspirin inhibits lipid peroxides and thromboxane but not prostacyclin in pregnant women. Am J Obstet Gynecol 1992; 167: 926–30
   PubMed Web of Science ®Google Scholar
• Walsh S W. Lipid peroxidation in pregnancy. Hypertens Pregn 1994; 13: 1–32
   Web of Science ®Google Scholar
• Weksler B B, Tack-Goldman K, Subramanian V A, Gay W A, Jr. Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis. Circulation 1985; 71: 332–40
   PubMed Web of Science ®Google Scholar
• Haus E, Nicolau G Y, Lakatua D, Sackett-Lundeen L. Reference values for chronopharmacology. Annual review of chronopharmacology, A Reinberg, M Smolensky, G Labrecque. Pergamon Press, Oxford 1988; Vol. 4: 333–424
   Google Scholar
• Haus E, Lakatua D, Swoyer J, Sackett-Lundeen L. Chronobiology in hematology and immunology. Am J Anatomy 1983; 168: 467–517
   PubMedGoogle Scholar
• Petralito A, Mangiafico R A, Gibiino S, Cuffari M A, Miano M F, Fiore C E. Daily modifications of plasma fibrinogen, platelet aggregation, Howell's time, PTT, TT and antithrombin III in normal subjects and in patients with vascular disease. Chronobiologia 1982; 9: 195–200
   PubMedGoogle Scholar
• Tofler G H, Brezinski D, Schafer A I, Czeisler C A, Rutherford J D, Willich S N, Gleason R E, Williams G H, Muller J E. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Eng J Med 1987; 316: 1514–18
   PubMed Web of Science ®Google Scholar
• Haus E, Cusulos M, Sackett-Lundeen L, Swoyer J. Circadian variations in platelet functions and blood coagulation parameters. Annual review of chronopharmacology, A Reinberg, M Smolensky, G Labrec-Que. Pergamon Press, Oxford 1990; Vol. 7: 153–56
   Google Scholar